Cipla Limited (CIPLA.NS)
| Previous close | 1,347.30 |
| Open | 1,347.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 1,335.00 - 1,357.70 |
| 52-week range | 896.30 - 1,519.00 |
| Volume | |
| Avg. volume | 1,653,083 |
| Market cap | 1.087T |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 29.29 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 8.50 (0.63%) |
| Ex-dividend date | 21 Jul 2023 |
| 1y target est | N/A |
- Reuters
India pharma companies develop versions of Wegovy to get in on weight-loss windfall
Indian drugmakers aiming to grab a slice of the burgeoning weight-loss treatment sales pie, both at home and abroad, have begun developing their own versions of Novo Nordisk's wildly in demand Wegovy. With some analysts predicting a weight-loss market reaching $100 billion a year or more by the end of the decade, executives at Sun Pharma, Cipla, Dr Reddy's and Lupin -- some of the world's largest generic drugmakers -- all said they have started work on Wegovy versions. Novo Nordisk has been unable to produce enough Wegovy to meet demand in more than half a dozen countries where it has already launched, amid record global obesity rates and people looking for easier alternatives to diet and exercise.
- Reuters
India shares close at two-week low as hawkish Fed spooks investors
India's benchmark indexes on Thursday closed at a two-week low in a broad-based selloff, after the U.S. Federal Reserve signalled that interest rates will remain elevated for longer. The Nifty 50 closed 0.8% lower at 19,742.35 points, its lowest close since Sept.7, while the S&P BSE Sensex declined about 0.85% to 66,230.24 points. The Fed on Wednesday held key interest rates unchanged as widely expected, but warned that the battle against inflation was far from over.
- Reuters
India's Torrent Pharma says nothing to disclose on Cipla stake buy report
India's Torrent Pharmaceuticals on Friday said it has no information requiring disclosure under listing regulations, after the Economic Times reported that it was in talks to buyout the stake of rival Cipla's top shareholders. Torrent said it "did not comment on speculative reports in the absence of verified data," and that it was not in a position to comment on the movement in its share price. Torrent Pharma is interested in buying out top shareholder Hamied family's 33.47% stake in Cipla and is trying to put together financing for the purchase, ET reported.
